KR100500299B1 - 영지추출물을 함유하는 치매의 예방 및 개선용 식품 조성물 - Google Patents
영지추출물을 함유하는 치매의 예방 및 개선용 식품 조성물 Download PDFInfo
- Publication number
- KR100500299B1 KR100500299B1 KR10-2004-0095239A KR20040095239A KR100500299B1 KR 100500299 B1 KR100500299 B1 KR 100500299B1 KR 20040095239 A KR20040095239 A KR 20040095239A KR 100500299 B1 KR100500299 B1 KR 100500299B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- ganoderma lucidum
- dementia
- iii
- ache
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 86
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 70
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 206010012289 Dementia Diseases 0.000 title claims abstract description 13
- 235000013305 food Nutrition 0.000 title claims description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 201000004810 Vascular dementia Diseases 0.000 claims abstract description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims abstract description 9
- -1 9-octadecenoyl Chemical group 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 5
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 40
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 abstract description 21
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 16
- 210000004556 brain Anatomy 0.000 abstract description 14
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 11
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 11
- 206010008118 cerebral infarction Diseases 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 8
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract description 7
- 210000005013 brain tissue Anatomy 0.000 abstract description 7
- 229960004373 acetylcholine Drugs 0.000 abstract description 6
- 230000000069 prophylactic effect Effects 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 229940022698 acetylcholinesterase Drugs 0.000 abstract description 4
- 230000001681 protective effect Effects 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- 102100033639 Acetylcholinesterase Human genes 0.000 description 40
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 38
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 23
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 21
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 21
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 21
- 229960002646 scopolamine Drugs 0.000 description 21
- 241000700159 Rattus Species 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 230000000638 stimulation Effects 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- 229960001685 tacrine Drugs 0.000 description 14
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 229960003530 donepezil Drugs 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000011260 co-administration Methods 0.000 description 9
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 8
- 102100032404 Cholinesterase Human genes 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000012549 training Methods 0.000 description 8
- 239000000401 methanolic extract Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 210000001715 carotid artery Anatomy 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 241000222336 Ganoderma Species 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 210000000269 carotid artery external Anatomy 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 210000004004 carotid artery internal Anatomy 0.000 description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 101150065749 Churc1 gene Proteins 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102100038239 Protein Churchill Human genes 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- NTBLZMAMTZXLBP-UHFFFAOYSA-M 2-acetylsulfanylethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=O)SCC[N+](C)(C)C NTBLZMAMTZXLBP-UHFFFAOYSA-M 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229940124810 Alzheimer's drug Drugs 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- MRZNYALJQXGMSQ-UHFFFAOYSA-N CCC(N)CC.CCC(N)CC Chemical compound CCC(N)CC.CCC(N)CC MRZNYALJQXGMSQ-UHFFFAOYSA-N 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- PLZVEHJLHYMBBY-UHFFFAOYSA-N Tetradecylamine Chemical compound CCCCCCCCCCCCCCN PLZVEHJLHYMBBY-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- IIPUKLNWLTUBKC-UHFFFAOYSA-N [I+].C(CCC)(=O)SCC[N+](C)(C)C Chemical compound [I+].C(CCC)(=O)SCC[N+](C)(C)C IIPUKLNWLTUBKC-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 125000005645 linoleyl group Chemical group 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- YRPQTVNCCVPGFA-FPLPWBNLSA-N palmitoleamide Chemical compound CCCCCC\C=C/CCCCCCCC(N)=O YRPQTVNCCVPGFA-FPLPWBNLSA-N 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
저해율(%) | |||||||||
10-2(M) | 10-3(M) | 10-4(M) | 10-5(M) | 10-6(M) | 10-7(M) | 10-8(M) | |||
R1 | 올레일 | 98 | 60 | 8 | - | - | - | ||
팔미토레일 | 99 | 58 | 44 | - | - | - | - | ||
미리스틸 | - | 75 | 10 | - | - | - | - | ||
R2 | 올레일 | - | 96 | 42 | 0.2 | - | - | - | |
리놀레일 | - | 70 | 3 | - | - | - | - | ||
미리스틸 | - | 97 | 44 | 5 | - | - | - | ||
96 | 32 | 0.5 | - | - | - | - | |||
대조군 | 도네페질 | - | - | - | - | 96 | 74 | 8 | |
타크린 | - | - | - | 99 | 83 | 43 |
Claims (6)
- GL-M, GL-M-8, GL-M-8-F, GL-M-8-F-b, GL-M-8-F-b-III, GL-M-8-F-b-III-1 중에서 선택된 하나이상의 유효분획을 포함하는 영지 추출물을 함유하는 치매의 예방 및 개선용 식품조성물
- 제 1항에 있어서, 상기 영지 추출물은 GL-M-8-F-b-III-1 임을 특징으로 하는 치매의 예방 및 개선용 식품조성물
- 하기 화학식 1의 화합물을 유효성분으로 함유하는 치매의 예방 및 개선용 식품 조성물상기 화학식 1에서 R1은 9-옥타데세노일(올레일), 9-헥사데세노일(팔미토레일) 또는 테트라데카노일(미리스틸)이다.
- 하기 화학식 2의 화합물을 유효성분으로 함유하는 치매의 예방 및 개선용 식품 조성물상기 화학식 2에서 R2는 9-옥타데세노일(올레일), 9,12-옥타데카디에노일(리놀레일) 또는 테트라데카노일(미리스틸)이다.
- 하기 화학식 3의 화합물을 유효성분으로 함유하는 치매의 예방 및 개선용 식품 조성물
- 제 1항 내지 제 5항 중 어느 한 항에 있어서, 알츠하이머성 치매와 혈관성 치매를 동시에 예방 및 개선하는 것을 특징으로 하는 식품 조성물
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010028285 | 2001-05-23 | ||
KR20010028285 | 2001-05-23 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-0028173A Division KR100502835B1 (ko) | 2001-05-23 | 2002-05-21 | 영지추출물, 올레아미드 및 그의 구조적 유사체를유효성분으로 함유하는 치매의 예방 및 치료용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040111240A KR20040111240A (ko) | 2004-12-31 |
KR100500299B1 true KR100500299B1 (ko) | 2005-07-11 |
Family
ID=27706061
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-0028173A KR100502835B1 (ko) | 2001-05-23 | 2002-05-21 | 영지추출물, 올레아미드 및 그의 구조적 유사체를유효성분으로 함유하는 치매의 예방 및 치료용 조성물 |
KR10-2004-0095239A KR100500299B1 (ko) | 2001-05-23 | 2004-11-19 | 영지추출물을 함유하는 치매의 예방 및 개선용 식품 조성물 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-0028173A KR100502835B1 (ko) | 2001-05-23 | 2002-05-21 | 영지추출물, 올레아미드 및 그의 구조적 유사체를유효성분으로 함유하는 치매의 예방 및 치료용 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (2) | KR100502835B1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100756890B1 (ko) * | 2005-08-19 | 2007-09-07 | 경희대학교 산학협력단 | 신경세포 보호활성을 갖는 올레산을 함유하는 조성물 |
KR100746592B1 (ko) * | 2007-03-30 | 2007-08-08 | 경희대학교 산학협력단 | 신경세포 보호활성을 갖는 올레산을 함유하는 퇴행성뇌질환의 예방 및 개선용 건강기능식품 |
KR20220075968A (ko) | 2020-11-30 | 2022-06-08 | 고려대학교 세종산학협력단 | 무 추출물을 포함하는 뇌 신경질환 예방, 개선 및 치료용 의약 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02188528A (ja) * | 1989-01-13 | 1990-07-24 | Tsurataka Tashiro | 痴呆症治療薬 |
JPH02188529A (ja) * | 1989-01-13 | 1990-07-24 | Tsurataka Tashiro | 血管障害治療薬 |
US5589182A (en) * | 1993-12-06 | 1996-12-31 | Tashiro; Renki | Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression |
JP2001322944A (ja) * | 2000-05-16 | 2001-11-20 | Kokusai Kanpo Kenkyusho:Kk | 漢方健康飲料およびこれに用いる抽出処理方法 |
JP5632317B2 (ja) * | 2011-03-19 | 2014-11-26 | 東京エレクトロン株式会社 | 冷却装置の運転方法及び検査装置 |
KR101198336B1 (ko) * | 2012-06-28 | 2012-11-06 | 전년하 | 전자유도 방식을 이용한 터치 스크린 패널용 태블릿 검사장치 및 검사방법 |
-
2002
- 2002-05-21 KR KR10-2002-0028173A patent/KR100502835B1/ko active IP Right Grant
-
2004
- 2004-11-19 KR KR10-2004-0095239A patent/KR100500299B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20020090140A (ko) | 2002-11-30 |
KR100502835B1 (ko) | 2005-07-20 |
KR20040111240A (ko) | 2004-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10160780B2 (en) | Compound extracted from husk and fruit stem of Xanthoceras sobifolia and its extracting method and use thereof | |
KR100188572B1 (ko) | 큐커비타 종의 신규 추출물, 그의 제조방법 및 약제와 화장품에 사용되는 그의 용도 | |
CN102212093B (zh) | 黄酮苷类化合物及其制备方法和用途 | |
JP4418675B2 (ja) | 神経細胞の保護のためのウチワサボテン抽出物又はそれから分離した化合物を用いた医薬組成物 | |
JP2005508974A6 (ja) | 神経細胞の保護のためのウチワサボテン抽出物又はそれから分離した化合物を用いた医薬組成物 | |
KR101916603B1 (ko) | 무청 추출물을 포함하는 뇌신경 질환의 예방, 개선 및 치료용 조성물 | |
KR100500299B1 (ko) | 영지추출물을 함유하는 치매의 예방 및 개선용 식품 조성물 | |
KR100665313B1 (ko) | 항산화 및 항바이러스 활성을 가지는 화합물 및 이를포함하는 감국 추출물 | |
KR100543897B1 (ko) | 치자 추출물 및 치자로부터 분리된 신규 화합물 및 그 용도 | |
WO2002094302A1 (en) | Compositions comprising extract of ganoderma lucidum, oleamide and its structural analogue as an effective component for preventing or treating dementia | |
KR101085219B1 (ko) | 뇌기능 개선 효능을 갖는 생약 추출물 | |
KR20150075047A (ko) | 여주 유래 프로토카테큐산을 활성성분으로 함유하는 인지기능 개선용 조성물 | |
KR101784294B1 (ko) | 모과 추출물을 포함하는 뇌신경질환 예방 또는 치료용 의약 조성물 | |
KR100963643B1 (ko) | 손바닥선인장 열매의 종자 추출물 또는 이로부터 분리된화합물을 함유하는 간독성 질환 예방 및 치료용 조성물 | |
KR101959551B1 (ko) | 애플민트 추출물을 유효성분으로 함유하는 피부 저색소증 개선 및 자외선으로부터 피부를 보호하기 위한 조성물 | |
JPH08231396A (ja) | 抗ヘリコバクター・ピロリ薬 | |
KR20070036431A (ko) | 항암 활성을 갖는 봄맞이 추출물 및 이로부터 분리된 트리테르펜 사포닌 화합물 | |
KR100767051B1 (ko) | 오보바톨 또는 오보바탈의 분리방법과 이를 유효성분으로함유하는 비만치료 및 예방용 조성물 및 상기 유효성분의정제방법 | |
KR100551718B1 (ko) | 지방산 합성효소의 활성을 억제할 수 있는 비만 억제용조성물 | |
JPH08208501A (ja) | ガルシニア マンゴスタナl.の抽出物を含有する抗ヘリコバクター・ピロリ薬 | |
EP1395270A1 (de) | Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch hepatitis b-viren | |
KR101006702B1 (ko) | 치매치료 효과를 갖는 신규 사포닌계 화합물 | |
KR102311887B1 (ko) | 괭생이모자반 추출물을 유효성분으로 포함하는 간질환 예방 또는 치료용 약학적 조성물 | |
KR100839131B1 (ko) | 오보바톨을 함유하는 아밀로이드 관련 질환의 치료 또는예방용 조성물 | |
KR100536163B1 (ko) | 암 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130515 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20140613 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20150724 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20161228 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20170628 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20180626 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20190404 Year of fee payment: 15 |